bearish
Chugai Pharmaceutical (4519 JP): Key Drugs Are Facing Competition; 2022 Target Seems Aggressive
332 Views06 Mar 2022 23:32
SUMMARY
- Chugai Pharmaceutical (4519 JP) shares declined 2% since we published our bearish note on the company in December. We remain bearish on the name.
- Chugai is betting big on Actemra, Hemlibra, and Ronapreve for achieving 2022 revenue target. However, these have bleak outlook due to competition and uncertainty regarding COVID-19 prevalence globally.
- Chugai does not have any big launches expected this year. Pipeline has less visibility for compensating the revenue loss from the patent expired products.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Chugai Pharmaceutical (4519 JP): Ronapreve Killed Joy in 2023; New Products to Drive Growth Ahead08 Feb 2024
- Chugai Pharmaceutical (4519 JP): Hemlibra Is the Only Saviour; Competition Bites Mainstay Drugs22 Jan 2023
- Chugai Pharmaceutical (4519 JP) 1Q22: Sales Growth Outshined by Weaker Margin; Guidance Unchanged17 May 2022
- Chugai Pharmaceutical (4519 JP): Actemra Loses Its Sheen on Arrival of Oral COVID-19 Pill30 Dec 2021
x